-
1 month ago | 
finanzen.net | Simon Conway |finanzen.net Redaktion
Werte in diesem Artikel Aktien 0,79 EUR -0,16 EUR -16,88% Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. ("Pharming” or "the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR)...
-
2 months ago | 
finanzen.net | Victoria Mitchell |finanzen.net Redaktion
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences.
-
2 months ago | 
finanzen.net | Victoria Mitchell |finanzen.net Redaktion
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences.
-
Jan 17, 2025 | 
finanzen.net | finanzen.net Redaktion
BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc.
-
Jan 17, 2025 | 
finanzen.net | Byd Aktie |finanzen.net Redaktion
FRIWO AG reorganizes its Executive Board and completes generational transitionDominik Wöffen and Ina Klassen new members of the Executive Board as of January 1, 2025 Former Co-CEO Rolf Schwirz becomes advisor to the Supervisory Board Contract with Roald Gréboval terminated prematurely by mutual agreementOstbevern, 17 January 2025 – With effect from January 1, 2025, FRIWO AG will reorganize its Group Executive Board.
-
Jan 17, 2025 | 
finanzen.net | finanzen.net Redaktion
Der iShares STOXX Global Select Dividend 100 ETF legte zuletzt zu und stieg im STU-Handel um 0,89 Prozent auf 0,26 EUR. Werte in diesem Artikel Der iShares STOXX Global Select Dividend 100 ETF legte bis auf 30,13 EUR an, der bisherige Tageshöchstkurs. Zur Startglocke stand der ETF bei 29,96 EUR. Zuletzt wurden via STU 370183 iShares STOXX Global Select Dividend 100 ETF-Anteilsscheine umgesetzt. Bei einem Wert von 30,78 EUR erreichte der ETF den höchsten Stand seit 52 Wochen (09.12.2024).
-
Jan 17, 2025 | 
finanzen.net | finanzen.net Redaktion
Die Kurse schickten den Vanguard FTSE Emerging Markets ETF nach oben. Im STU-Handel gewann der Fonds zuletzt 1,37 Prozent auf 0,80 EUR. Werte in diesem Artikel Der Vanguard FTSE Emerging Markets ETF kletterte in der Spitze bis auf 59,12 EUR. Zur Börseneröffnung tendierte der Fonds bei 58,19 EUR. Bisher wurden via STU 118526 Vanguard FTSE Emerging Markets ETF-Anteilsscheine gekauft oder verkauft. Der Fonds kletterte am 09.12.2024 auf bis zu 61,08 EUR und markierte damit ein 52-Wochen-Hoch.
-
Jan 17, 2025 | 
finanzen.net | finanzen.net Redaktion
FORESIGHT VENTURES VCT PLC LEI: 213800R88MRC4Y3OIW86DIVIDEND DECLARATION17 JANUARY 2025 The Board is pleased to declare an interim dividend of 2.0p per share, which will be paid on 14 March 2025. The shares will be quoted ex-dividend on 27 February 2025 and the record date for payment will be 28 February 2025.
-
Jan 17, 2025 | 
finanzen.net | finanzen.net Redaktion
Harvia Plc, Stock Exchange Release, January 17, 2025 at 4.00 PM EET The Shareholders’ Nomination Board of Harvia Plc proposes the following to the Annual General Meeting planned to be held on 8 April 2025: Number of members of the Board of Directors The Nomination Board proposes that the number of members of the Board of Directors will be increased from six to seven.
-
Jan 17, 2025 | 
finanzen.net | finanzen.net Redaktion
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention.
